Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition

Niu,Chang-Chun; Zhao,Chen; Yang,Zhen-Dong; Zhang,Xiao-Li; Wu,Wei-Ru; Pan,Jing; Zhao,Chen; Li,Zhi-Qiang; Ding,Wei; Yang,Zhong; Si,Wei-Ke

doi:10.3892/ijmm.2012.1207

Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition

Authors:
- Chang-Chun Niu
- Chen Zhao
- Zhen-Dong Yang
- Xiao-Li Zhang
- Wei-Ru Wu
- Jing Pan
- Zhi-Qiang Li
- Wei Ding
- Zhong Yang
- Wei-Ke Si
View Affiliations

Affiliations: Department of Clinical Hematology, The Third Military Medical University, Chongqing 400038, P.R. China, Department of Clinical Laboratory, The 154th Central Hospital, Xinyang, Henan 464000, P.R. China, Department of Orthopedics, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400038, P.R. China
Published online on: December 6, 2012 https://doi.org/10.3892/ijmm.2012.1207
Pages: 453-458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

γ-catenin plays different roles in different types of tumors, and its role in chronic myeloid leukemia (CML) cells has yet to be identified. In our study, two CML cell lines (K562, KU812) had higher γ-catenin expression levels compared to five types of BCR-ABL-negative leukemia cells. Knockdown of the expression of BCR-ABL resulted in downregulation of γ-catenin. Furthermore, downregulation of γ-catenin by siRNA inhibited the proliferation and colony formation of CML cells and the expression of the c-Myc and cyclin D1 genes; downregulation of γ-catenin also potentiated the effects of imatinib (inhibiting CML cell proliferation and inducing apoptosis) and suppressed the anti-apoptotic genes Bcl-xL and survivin. We also showed that downregulation of γ-catenin suppressed the phosphorylation of STAT5, promoted the phosphorylation of β-catenin and reduced the translocation of β-catenin into the nucleus, although there were no effects on the total level of β-catenin expression in the whole cells. Furthermore, downregulation of γ-catenin was found to promote glycogen synthase kinase-3β (GSK3β) and inhibit its phosphorylation. Collectively, our results suggest that γ-catenin is an oncogene protein in CML that can be regulated by BCR-ABL and that suppression of γ-catenin inhibits CML cell growth and potentiates the effects of imatinib on CML cells through inhibition of the activation of STAT5 and suppression of β-catenin by activating GSK3β.

View Figures

View References

1.	Peifer M, McCrea PD, Green KJ, Wieschaus E and Gumbiner BM: The vertebrate adhesive junction proteins beta-catenin and plakoglobin and the Drosophila segment polarity gene armadillo form a multigene family with similar properties. J Cell Biol. 118:681–691. 1992. View Article : Google Scholar : PubMed/NCBI
2.	Zhurinsky J, Shtutman M and Ben-Ze’ev A: Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci. 113:3127–3139. 2000.PubMed/NCBI
3.	Barker N and Clevers H: Catenins, Wnt signaling and cancer. Bioessays. 22:961–965. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Zhurinsky J, Shtutman M and Ben-Ze’ev A: Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol. 20:4238–4252. 2000. View Article : Google Scholar : PubMed/NCBI
5.	Miravet S, Piedra J, Miro F, Itarte E, Garcia de Herreros A and Dunach M: The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin. J Biol Chem. 277:1884–1891. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Aktary Z and Pasdar M: Plakoglobin: role in tumorigenesis and metastasis. Int J Cell Biol. 2012:1895212012. View Article : Google Scholar : PubMed/NCBI
7.	Sadot E, Simcha I, Iwai K, Ciechanover A, Geiger B and Ben-Ze’ev A: Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene. 19:1992–2001. 2000. View Article : Google Scholar : PubMed/NCBI
8.	Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D and Ben-Ze’ev A: Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol. 133:199–209. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Parker HR, Li Z, Sheinin H, Lauzon G and Pasdar M: Plakoglobin induces desmosome formation and epidermoid phenotype in N-cadherin-expressing squamous carcinoma cells deficient in plakoglobin and E-cadherin. Cell Motil Cytoskeleton. 40:87–100. 1998. View Article : Google Scholar
10.	Winn RA, Bremnes RM, Bemis L, et al: gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene. 21:7497–7506. 2002. View Article : Google Scholar : PubMed/NCBI
11.	Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD and Lobie PE: Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA. 101:15166–15171. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Rieger-Christ KM, Ng L, Hanley RS, et al: Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer. 92:2153–2159. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Pan H, Gao F, Papageorgis P, Abdolmaleky HM, Faller DV and Thiagalingam S: Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther. 6:1638–1643. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Kolligs FT, Kolligs B, Hajra KM, et al: gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev. 14:1319–1331. 2000.PubMed/NCBI
15.	Hazlehurst LA, Bewry NN, Nair RR and Pinilla-Ibarz J: Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control. 16:100–107. 2009.PubMed/NCBI
16.	Quintas-Cardama A and Cortes J: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Muller-Tidow C, Steffen B, Cauvet T, et al: Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 24:2890–2904. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Zhao C, Blum J, Chen A, et al: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 12:528–541. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Coluccia AM, Vacca A, Dunach M, et al: Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 26:1456–1466. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Kim YM, Ma H, Oehler VG, et al: The gamma catenin/CBP complex maintains survivin transcription in beta-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets. 11:213–225. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Yuan Y, Niu CC, Deng G, et al: The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. Int J Mol Med. 27:63–69. 2011.PubMed/NCBI
22.	He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
23.	Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
24.	Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ and Boman BM: Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61:8664–8667. 2001.
25.	de Groot RP, Raaijmakers JA, Lammers JW and Koenderman L: STAT5-dependent cyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun. 3:299–305. 2000.PubMed/NCBI
26.	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.
27.	Gaiger A, Henn T, Horth E, et al: Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 86:2371–2378. 1995.PubMed/NCBI
28.	Sawyers CL, Callahan W and Witte ON: Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 70:901–910. 1992. View Article : Google Scholar : PubMed/NCBI
29.	Afar DE, McLaughlin J, Sherr CJ, Witte ON and Roussel MF: Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci USA. 92:9540–9544. 1995. View Article : Google Scholar : PubMed/NCBI
30.	Williamson L, Raess NA, Caldelari R, et al: Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J. 25:3298–3309. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Diamond JM and Melo JV: Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma. 52(Suppl 1): S12–S22. 2011. View Article : Google Scholar
32.	Wang Z, Sampath J, Fukuda S and Pelus LM: Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 65:8224–8232. 2005. View Article : Google Scholar : PubMed/NCBI
33.	Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON and Green DR: Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 16:1383–1390. 1998. View Article : Google Scholar : PubMed/NCBI
34.	Dusek RL, Godsel LM, Chen F, et al: Plakoglobin deficiency protects keratinocytes from apoptosis. J Invest Dermatol. 127:792–801. 2007. View Article : Google Scholar : PubMed/NCBI
35.	Salomon D, Sacco PA, Roy SG, et al: Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J Cell Biol. 139:1325–1335. 1997. View Article : Google Scholar : PubMed/NCBI
36.	Li L, Chapman K, Hu X, Wong A and Pasdar M: Modulation of the oncogenic potential of beta-catenin by the subcellular distribution of plakoglobin. Mol Carcinog. 46:824–838. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Kodama S, Ikeda S, Asahara T, Kishida M and Kikuchi A: Axin directly interacts with plakoglobin and regulates its stability. J Biol Chem. 274:27682–27688. 1999. View Article : Google Scholar : PubMed/NCBI